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Abstract
Background Fetal antiretroviral exposure is usually
derived from the cord-to-maternal concentration ratio. This
static parameter does not provide information on the
pharmacokinetics in utero, limiting the assessment of a
fetal exposure–effect relationship.
Objective The aim of this study was to incorporate pla-
cental transfer into a pregnancy physiologically based
pharmacokinetic model to simulate and evaluate fetal
darunavir exposure at term.
Methods An existing and validated pregnancy physiolog-
ically based pharmacokinetic model of maternal darunavir/
ritonavir exposure was extended with a feto-placental unit.
To parameterize the model, we determined maternal-to-
fetal and fetal-to-maternal darunavir/ritonavir placental
clearance with an ex-vivo human cotyledon perfusion
model. Simulated maternal and fetal pharmacokinetic
profiles were compared with observed clinical data to
qualify the model for simulation. Next, population fetal
pharmacokinetic profiles were simulated for different
maternal darunavir/ritonavir dosing regimens.
Results An average (±standard deviation) maternal-to-fe-
tal cotyledon clearance of 0.91 ± 0.11 mL/min and fetal-
to-maternal clearance of 1.6 ± 0.3 mL/min was deter-
mined (n = 6 perfusions). Scaled placental transfer was
integrated into the pregnancy physiologically based phar-
macokinetic model. For darunavir 600/100 mg twice a day,
the predicted fetal maximum plasma concentration, trough
concentration, time to maximum plasma concentration, and
half-life were 1.1, 0.57 mg/L, 3, and 21 h, respectively.
This indicates that the fetal population trough concentra-
tion is higher or around the half-maximal effective dar-
unavir concentration for a resistant virus (0.55 mg/L).
Conclusions The results indicate that the population fetal
exposure after oral maternal darunavir dosing is therapeutic
and this may provide benefits to the prevention of mother-
to-child transmission of human immunodeficiency virus.
Moreover, this integrated approach provides a tool to
prevent fetal toxicity or enhance the development of more
selectively targeted fetal drug treatments.
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Key Points
Fetal exposure to maternally administered
medication is an important determinant of fetal drug
toxicity or efficacy. Darunavir crosses the placenta
and is frequently used in pregnancy.
We can predict fetal exposure to darunavir, co-
administered with ritonavir, by integrating human
ex-vivo placental transfer and physiologically based
pharmacokinetic modeling.
The placental perfusion setup is a valuable
experimental tool that can be integrated with
physiologically based pharmacokinetic modeling to
simulate fetal drug exposure to darunavir during
pregnancy. Fetal darunavir trough concentration is
just above the half-maximal effective concentration
for wild-type human immunodeficiency virus and
may benefit the prevention of mother-to-child
transmission.
The approach described in this study can be used to
optimize maternal pharmacotherapy to prevent fetal
toxicity or enhance the development of more
selectively targeted fetal drug treatments.
1 Introduction
Many women use medications during the course of their
pregnancy for different reasons [1, 2]. For ethical and
practical considerations, however, pregnant women are
generally excluded from clinical studies [3–5]. Conse-
quently, for the large majority of medications used during
pregnancy, there is inadequate or no information on fetal
exposure and safety. This imposes severe limitations on
drug therapy during pregnancy as placental transfer
potentially poses a threat to fetal well-being. However, it
may allow drugs to be administered to the mother for
therapeutic benefit of the fetus in utero.
Experimentally, fetal drug exposure remains difficult to
quantify, as the fetus and placenta are not readily acces-
sible for sampling until delivery. Sampling of umbilical
cord blood and maternal blood at the time of delivery is an
ethically acceptable and easily accessible method, allowing
the calculation of a cord blood-to-maternal blood concen-
tration ratio. Though a cord blood-to-maternal blood con-
centration ratio is a clinically useful index of relative fetal
drug exposure, there is often large variability between
mother-infant pairs owing to variability in the timing of the
sample collection relative to the last maternal dose and it
does not provide any information on the fetal concentra-
tion–time profile [6, 7]. Ex-vivo dual-side perfusion of a
single human placental cotyledon has proven to be a clin-
ically relevant model for studying placental transport of
various endogenous compounds and xenobiotics [6].
Although this model gives a good estimate of placental
transfer, it does not provide information on in-vivo fetal
pharmacokinetics and exposure.
Physiologically based pharmacokinetic (PBPK) models
may provide a solution. Such models incorporate preg-
nancy-induced changes in various physiological and
anatomical parameters and represent a feasible approach
for appropriate dose optimization in pregnant women [8].
A number of pregnancy PBPK (p-PBPK) models have been
developed to predict the disposition of various drugs in
pregnant women; however, these models are mainly related
to maternal pharmacokinetics [9–12].
It remains a challenge to predict fetal drug exposure
using p-PBPK models that include human placental
transfer parameters. Various animal models have been
used to study placental drug transfer, but data are of poor
translational value because of interspecies variability in
placental structure and hemodynamics [6, 13]. Very few
p-PBPK models include actual human placental transfer
parameters from ex-vivo placenta perfusion experiments
[14, 15]. Such parameters are obtained by using intact
placental tissue with corresponding hemodynamics and
should include active as well as passive drug transfer
processes.
Darunavir administered once daily (QD) or twice daily
(BID), in combination with low-dose ritonavir (darunavir/
ritonavir) is a preferred agent to be used in human
immunodeficiency virus (HIV)-positive pregnant women
[16]. In plasma, darunavir is approximately 94% protein
bound, mainly to a-1-acid glycoprotein (AAG). Bio-
transformation is almost exclusively mediated by cyto-
chrome P450 (CYP) 3A4. Clinically, darunavir is co-
administered with the potent CYP3A4 inhibitor ritonavir,
to reduce darunavir clearance and maintain higher plasma
concentrations throughout the dosing interval [12].
Ritonavir is also known to have potent inhibitory effects
on the efflux drug transporter, P-glycoprotein (P-gp),
which in the intestine, may contribute to the increased
darunavir bioavailability [17]. Recently, we reported on a
whole-body p-PBPK model to describe the maternal
pharmacokinetics of ritonavir-boosted darunavir in preg-
nancy [12]. Darunavir was considered a good candidate
for further development of the p-PBPK model by
including placental transfer and an in-utero compartmen-
tal structure because clinical data on its pharmacokinetics
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in pregnancy and cord blood concentrations are available
[18].
In this study, the main focus was to develop a p-PBPK
model to quantitatively predict fetal exposure to the
antiretroviral compound, darunavir, co-administered with
ritonavir. To achieve this, a previously developed p-PBPK
model of darunavir [12] was extended by incorporating a
feto-placental unit into the maternal model. Bi-directional
placental transfer parameters for darunavir were deter-
mined using the ex-vivo, dual-sided, perfused isolated
cotyledon model.
2 Methods
Maternal-to-fetal (MTF) transfer of darunavir has been
previously studied with the ex-vivo cotyledon perfusion
model [19]. In contrast to this study, we included ritonavir
and evaluated MTF and fetal-to-maternal (FTM) placental
darunavir transfer to account for the potential interaction
with placental drug transporters [20]. In brief, placental
transfer parameters for darunavir were determined using
the ex-vivo, dually perfused, isolated cotyledon model.
Next, the p-PBPK model of darunavir developed previ-
ously [12] was extended by a feto-placental unit including
placental transfer based on ex-vivo data using Berkeley
Madonna software (Berkeley Madonna Inc, California).
After model parameterization, simulated maternal and fetal
pharmacokinetic profiles were compared with observed
clinical data.
2.1 Placenta Perfusion
The study was approved by the local Ethics Committee of
Radboud University Medical Center, Nijmegen, the
Netherlands (file number 2014-1397). The experimental
setup and methodology were detailed previously [21]. The
Electronic Supplementary Material provides more details
and specifications on the ex-vivo placenta perfusions and
bioanalyses.
2.2 Modeling
A full-body PBPK model comprising 13 tissue/organ
compartments was built and coded in Berkeley Madonna
syntax, Version 8.3.23.0 (http://www.berkeleymadonna.
com/). The model was largely based on the darunavir/ri-
tonavir p-PBPK model developed in Simcyp Version 13
release 2 (Simcyp Limited, a Certara company, Sheffield,
UK), and described previously for maternal darunavir
pharmacokinetics [12]. All Berkeley Madonna codes are
available upon request. No model fitting and/or parameter
estimation was performed in the current study.
2.3 Physiologically Based Pharmacokinetic Model
Development
Human physiological parameters were obtained from liter-
ature as well as from virtual populations of healthy volun-
teers and pregnant women implemented in Simcyp.
Physicochemical and in-vitro pharmacokinetic parameters
of darunavir and ritonavir were obtained from literature [12].
First, a PBPK model was developed for darunavir in non-
pregnant women for oral administration. The model was
validated by comparing simulations with observed in-vivo PK
profiles obtained after oral administration of standard dosages.
Once the PBPK model was evaluated in the non-pregnant
population, all drug-specific parameters were fixed and
pregnancy-specific changes in physiological parameters were
incorporated. Model performance was verified by comparing
simulations with observed concentrations in pregnant women
[22] as well as with the previously developed p-PBPK model
of Colbers et al. [12]. The p-PBPK model was extended by
incorporation of a feto-placental unit (Fig. 1). Simulated fetal
plasma darunavir concentrations were compared with repor-
ted cord blood concentrations. Only population parameters
Fig. 1 Final pregnancy physiologically based pharmacokinetic
model including the feto-placental unit. EHR enterohepatic recircu-
lation, fa fraction absorbed, CLaf estimated clearance from amniotic
fluid to fetal blood, CLfa estimated clearance from fetal blood to
amniotic fluid, CLhepatic hepatic clearance, CLfm fetal-to-maternal
placental clearance, CLmf maternal-to-fetal placental clearance, Q re-
spective tissue/organ blood flow. The subscripts are denoted as
follows: ad adipose, bo bone, br brain, he heart, ki kidney, lu lung, mu
muscle, sk skin, sp spleen, gu gut, li liver, RoB rest of fetal body
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were considered and individual variability was not included.
We conducted sensitivity analyses to assess the impact of
changes in feto-placental-related parameters on fetal plasma
concentration–time profiles.
Additionally, we explored the influence of different
darunavir/ritonavir dosing regimens on fetal exposure. This
was mainly done to illustrate its usefulness for assessing
exposure–response relations. For this purpose, we assumed
a minimum effective fetal plasma Ctrough of 0.55 mg/L.
This is based on the half-maximal effective darunavir
concentration for resistant HIV, a target frequently used in
therapeutic drug monitoring [23].
3 Results
3.1 Ex-vivo Perfusion of Human Placental
Cotyledon
A total of 15 placentas were collected from elective Cae-
sarean sections (n = 8) and uncomplicated vaginal
deliveries (n = 7). Six perfusions fulfilled the quality cri-
teria for successful perfusion. On average, perfusion was
started within 45 min of delivery; which is consistent with
previous studies [24]. We conducted a perfusion experi-
ment without placental tissue and found no indications for
system adherence of darunavir and ritonavir (data not
shown).
The concentration–time profiles of the FTM and MTF
perfusion experiments are shown in Fig. 2a, c. Assuming
that the amounts in the maternal, fetal, and placental
compartments at each time point sum up to the total
amount (100%) added at t = 0, the placental content was
calculated (Fig. 2b, d). This was based on the absence of
system adherence and the presumed absence of darunavir
biotransformation in the perfused cotyledon. Sampling
from the cotyledon over the course of the experiment was
not feasible as it would have caused leakage. After each
experiment, a cotyledon tissue sample was taken for bio-
analyses (Fig. 2a, c). In the mass balance calculation, we
accounted for volume and darunavir loss because of sam-
pling. Darunavir did not accumulate in placental tissue. Bi-
Fig. 2 Darunavir concentration–time and mass-balance profiles in
ex-vivo placenta perfusion. Placental transfer of darunavir in the
presence of ritonavir over 150 or 180 min of perfusion. a Maternal-to-
fetal transfer; data represent darunavir concentrations in the maternal
reservoir (filled circles), maternal outflow (open circles), and fetal
outflow (open triangles) after administration of darunavir/ritonavir (6/
0.5 mg/L) to the maternal circulation at t = 0 min. b Maternal-to-
fetal transfer; accumulation, and mass balance calculation (expressed
as percentage of the initial maternal reservoir concentration) showing
that tissue concentrations reach steady state at t = 60 min. c Fetal-to-
maternal transfer; data represent darunavir concentrations in the fetal
reservoir (filled triangles), fetal outflow (open triangles), and
maternal outflow (open circles) after administration of darunavir/
ritonavir (6/0.5 mg/L) to the fetal circulation at t = 0 min. Placental
tissue concentrations at the end of the perfusion are shown as stars.
d Fetal-to-maternal transfer; accumulation, and mass balance calcu-
lation (expressed as percentage of the initial fetal reservoir concen-
tration) showing that tissue concentrations reach steady state at
t = 60 min
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directional clearances were determined based on linear
regression analysis of natural log-transformed darunavir
concentrations in the closed reservoir after 60 min.
The MTF and FTM cotyledon clearances were calcu-
lated as follows:
Ex-vivo cotyledon clearance
CLcot ¼ ke  V; ð1Þ
where CLcot represents the mean cotyledon clearance val-
ues, V is the volume of the perfusion reservoir, and ke is a
placental elimination constant derived from the slope of the
natural log concentration–time profile (MTF, R2 = 0.994;
FTM, R2 = 0.976).
3.2 Development and Verification of a Darunavir/
Ritonavir Physiologically Based
Pharmacokinetic Model Model in Non-Pregnant
Subjects
Time-based differential equations used to describe changes
in drug concentrations in various organ compartments were
as follows:
Maternal non-eliminating tissue compartments (perfu-
sion limited)
Vtissue
dCtissue
dt
¼ Qt  Carterial  Ctissue
Kpt
 BP
 
; ð2Þ
Well-stirred liver model
Vliver
dCliver
dt
¼ Qha  Carterial þ Qsp  Csp
Kpsp
 BP
 !
þ Qgu  Cgu
Kpgu
 BP
 !
 Qli  Cli
Kpli
 BP
 
 CLintmet  fuli  Cli;
ð3Þ
where V, Cli, Carterial, Csp, and Cgu are volumes, drug
concentrations in liver, arterial blood, spleen, and gut,
respectively. The parameter Q denotes the respective blood
flow in or out of the organ/tissue. CLhepatic, BP, and Kp are
total hepatic clearance, blood-to-plasma ratio, and tissue-
to-plasma partition coefficient, respectively. The subscripts
ha, sp, gu, li, and t denote the hepatic artery, spleen, gut,
liver, and tissue, respectively.
Absorption was defined by a one-compartment model
with first-order absorption rate, ka. Drug administered in
the dosing compartment (gut lumen) is absorbed into the
gut wall, from which the drug is released into the portal
circulation.
Perfusion-limited distribution kinetics was used for all
non-eliminating tissues; hence, passive diffusion from
plasma into tissue and homogenous distribution across the
tissue mass was assumed. Tissue-to-plasma partition
coefficients (Kp) used in this model were previously pre-
dicted by us in Simcyp, using the Rodgers and Rowland
method [12, 25]. Because a well-stirred liver model (per-
fusion-limited) resulted in substantial overestimation of
darunavir exposure (in the absence of ritonavir) [12], a
permeability-limited liver model including active uptake of
the drug into the liver was used for the previous p-PBPK
model of darunavir in pregnancy. In addition, empirical
clinical data exist suggesting permeability-limited distri-
bution into the eliminating tissues [26]. However, full
parameterization of such a model requires data on activity
and abundance of the drug transporters involved, which are
currently not available. Because the scope of this work was
mainly related to fetal pharmacokinetics, we used a sim-
plified and refined well-stirred liver model against the
background of their permeability-limited liver model,
which includes active uptake of the drug into the liver. In
refining the well-stirred liver model, we assumed that drug
exchange in the liver is primarily driven by passive diffu-
sion between plasma and the interstitial space; and that
there is active transporter-mediated uptake of drug into the
cell, in addition to passive diffusion. This leads to
increased intracellular darunavir availability and thus,
biotransformation.
Based on steady-state conditions, we derived the fol-
lowing equation:
CuLi ¼ Cup  UF; ð4Þ
where Cup is the unbound plasma concentration of drug,
CuLi is the unbound drug concentration in the liver, and UF
is an uptake ratio. The uptake parameter, UF, was esti-
mated by fitting model simulations against the observed
clinical data (darunavir/ritonavir 600/100 mg in non-preg-
nant adults) presented by Rittweger et al. (27). An optimal
UF of 1.2 was estimated against the background of free
plasma-to-tissue concentration ratio predicted in Simcyp
[12] and observed in vivo [28].
Systemic clearance of darunavir was considered to
mainly occur via the liver; therefore, renal clearance was
not included in the model [27]. Because enterohepatic
recirculation of darunavir was a major determinant in
modeling the interaction of darunavir with ritonavir in the
existing p-PBPK model, and was suggested in a previous
clinical study [29], an enterohepatic recirculation parame-
ter was added to the current model as an empirical solution
by visually fitting the simulated PK profile to the observed
clinical data (non-pregnant). The enterohepatic recircula-
tion was defined as a constant fraction of the modeled
darunavir dose available for re-absorption from the gut
lumen. This is based on the assumption that a small
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fraction of darunavir amount is excreted through biliary
clearance to the gut lumen.
The darunavir-ritonavir drug–drug interaction model
used includes both competitive and mechanism-based
inhibition of CYP3A4 activity. A static ritonavir plasma
concentration was used for inhibition. Different population
ritonavir unbound steady-state Ctrough were used for BID
and QD dosing, and for the pregnant and non-pregnant
simulations [22]. Predicted PK profiles were in line with
observed clinical data as well as with the simulated PK
profiles by Colbers et al. (Fig. 3).
3.3 Development and Verification of a Darunavir/
Ritonavir Physiologically Based
Pharmacokinetic Model Model in Pregnant
Subjects
After successful simulation of PK profiles in non-pregnant
subjects, physiological parameters were modified to reflect
changes in pregnancy, while keeping all drug-specific
parameters constant. Physiological and metabolic changes
(e.g., body weight and CYP enzyme activity) with gesta-
tional age were implemented using data and algorithms
described previously [30]. Variations in protein binding
during pregnancy as well as in the fetus at term were
implemented in the model based on algorithms from
Simcyp, assuming the absence of changes in protein
binding kinetics. Further details on model parameterization
were described previously [12].
The PK profile of darunavir was simulated in pregnant
women (gestational age = 38 weeks) for a steady-state
situation of the clinical dosage regimens 600/100 mg BID
as well as 800/100 mg QD. Visual inspection of the curves
showed that the simulated PK profile was in line with
observed clinical data as well as simulated PK profiles of
Colbers et al. [12] (Fig. 4a, b). Based on this verification,
we considered the model suitable for extension with a feto-
placental unit to simulate fetal PK profiles.
3.4 Incorporation of a Feto-Placental Unit
3.4.1 Scaling Ex-Vivo Cotyledon Darunavir Clearance
to In-Vivo Placental Clearance
The ex-vivo cotyledon clearance of darunavir determined
from the perfusion experiments was scaled to in-vivo pla-
cental clearance. Because darunavir displays a substantial
degree of protein binding (94%) in plasma, it was neces-
sary to assess the free darunavir fraction in the perfusion
samples (containing 30 g/L albumin) to calculate an
unbound cotyledon clearance. The mean, concentration-
independent, protein-free fraction of darunavir in the per-
fusion medium was 16% ± 0.5% (n = 5). Second, the
unbound cotyledon clearance was extrapolated to in-vivo
cotyledon clearance, taking into account the respective
protein-free fractions in maternal and fetal blood and the
average number of cotyledons in a placenta (Table 1).
The equations used are as follows:Scaled placental
clearance
CLmf ¼ fup  CLcotmf= fuperf
  Ncot;
CLfm ¼ fupF  CLcotfm= fuperf
   Ncot; ð5Þ
where Ncot denotes the average number of cotyledons per
placenta, CLcot, mf is the MTF cotyledon clearance,
CLcot, fm is the FTM cotyledon clearance, fuperf is the
protein-free fraction in the perfusion medium, CLmf is in-
vivo MTF placental clearance, CLfm is in-vivo FTM pla-
cental clearance, fup is the fraction unbound in maternal
plasma, and fupF is the fraction unbound in fetal plasma.
Fig. 3 Simulation of maternal (non-pregnant) darunavir concentra-
tion–time profiles. Simulation of maternal (non-pregnant) darunavir
pharmacokinetic profiles at steady state for darunavir/ritonavir (DRV/
r) dosing regimens of a 600/100 mg twice daily (BID) and b 800/
100 mg once daily (QD). These simulations are compared with
previous physiologically based pharmacokinetic simulations [12], as
well as observed clinical data [22]. conc. concentration
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Variations in protein binding in maternal and fetal blood
were taken into account in this model. Fraction of unbound
drug in maternal and fetal blood was predicted from
algorithms available in Simcyp, assuming the absence of
changes in binding kinetics for AAG, the predominant
binding protein for darunavir [12, 27]. However, fetal
plasma AAG levels are appreciably lower than in the
maternal circulation (fetal:maternal AAG ratio = 0.37)
[6]. Predicting the darunavir fraction unbound in fetal
plasma based on AAG as the primary binding protein and
assuming an average fetal AAG level at term of 0.17 g/L
[6], resulted in a predicted fupF of 0.22. This value is higher
than the unbound fraction (fuperf) of 0.16 determined in the
experimental placenta perfusion medium in the absence of
AAG, but in the presence of albumin (30 g/L). This indi-
cates that in vivo, albumin (33.5 g/L) may be more
important in binding darunavir in the fetal circulation [31]
relative to the low AAG levels. Therefore, predictions of
the darunavir fraction unbound in the fetal circulation were
based on albumin levels. The predicted fraction unbound in
maternal and fetal blood were 0.12 and 0.27, respectively.
Fig. 4 Simulation of maternal and fetal darunavir concentration–time
profiles. Simulation of maternal and fetal plasma darunavir pharma-
cokinetic profiles at steady state for darunavir/ritonavir (DRV/r)
dosing regimens of a 600/100 mg twice daily (BID) and b 800/
100 mg once daily (QD). Simulated fetal plasma darunavir
concentrations compared with observed cord blood concentrations
for the maternal doses of c 600/100 mg BID and d 800/100 mg OD.
These simulations are compared with previous pregnancy physiolog-
ically based pharmacokinetic simulations [12], as well as observed
clinical data [18, 22]. conc. concentration, GA gestational age
Table 1 In-vitro and physiological parameters for the feto-placental
unit
Parameter; gestational age: 38 weeks Value References
Fetal cardiac output, Qfco (L/h) 85.5 [32]
Fetal weight (kg) 3.56 [30]
Amniotic fluid volume (L) 0.86 [14, 30]
Fetal blood volume, VbloodFetal (L) 0.24 [44]
DRV CLaf (L/h) 0.04 Estimated
DRV CLfa (L/h) 0.08 Estimated
DRV CLcot, mf (mL/min) 0.91 ± 0.11 Determined
DRV CLcot, mf (mL/min) 1.6 ± 0.3 Determined
Ncot 30 [45]
DRV fuperf 0.16 Determined
Hct 50% [31]
CLaf amniotic fluid-to-fetal blood clearance, CLfa fetal blood-to-am-
niotic fluid clearance, CLcot, fm fetal-to-maternal cotyledon clearance,
CLcot, mf maternal-to-fetal cotyledon clearance, fuperf free fraction of
darunavir in perfusion medium, Hct hematocrit, Ncot average number
of cotyledons per placenta
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3.4.2 Fetal Physiologically Based Pharmacokinetics
of Darunavir/Ritonavir
The placenta was considered as a barrier between maternal
and fetal blood. The fetal compartment was split into fetal
blood and rest of fetal body (Fig. 1). During late pregnancy,
20% of fetal cardiac output is distributed to the placenta, with
the remaining 80% distributed to the rest of the fetal body
(QRoB; Fig. 1) [32]. Fetal tissues were lumped into one
compartment. Tissue partitioning was based on reported
adult Vss, assuming linearity between volume of distribution
and body volume [12]. Although there may be differences in
fetal Vss and adult Vss, no data are currently available to
address such differences. Moreover, within-species Vss is
usually well predicted by allometry [33].
Darunavir is also reported to distribute into amniotic
fluid up to *25% of maternal concentrations [34].
Although these data are limited, we assumed slow mass
transfer (Table 1) from and into amniotic fluid to reach a
steady-state amniotic concentration of about 25%. Mass
transfer was assumed to be relatively slow compared with
placental clearance because the processes of excretion and
absorption into and from amniotic fluid are likely to be
much slower than placental clearance.
Because of low abundance and activity of CYP3A enzymes
in the placenta [35], it was assumed in this study that there was
negligible placental metabolism of darunavir. Furthermore, in
the presence of ritonavir, we would expect any remaining
placental CYP metabolism to be completely inhibited. In
addition, the relevance of fetal hepatic metabolism was
assumed to be negligible and therefore not taken into account.
Although large variability is reported, relative CYP3A4 gene
expression was found to be 40,000 times higher in adults than
in fetuses, whereas CYP3A7 expression was 5500 higher in
fetuses than in adults [36]. It cannot be excluded that in utero
other CYP450 enzymes (e.g., CYP3A7) may be involved in
the biotransformation of darunavir. More research is needed to
generate adequate data to be able to incorporate fetal hepatic
metabolism into p-PBPK models in a mechanistic manner.
Darunavir disposition in the feto-placental unit was
described as follows:
Fetal blood
VbloodF
dCbloodF
dt
¼ CLmf  Cart  CLfm  CbloodF
þ QrobF  CrobF
KprobF
 BPF  CbloodF
 
 CbloodF  CLfa þ CLaf  Camf ; ð6Þ
Fetal body
VrobF
dCrobF
dt
¼ QrobF  CbloodF  CrobF
KprobF
 BPF
 
; ð7Þ
Amniotic fluid
Vamf
dCamf
dt
¼ CbloodF  CLfa  CLaf  Camf ; ð8Þ
where CLmf denotes MTF placental clearance, CLfm is the
FTM placental clearance, BPF is the fetal blood-to-plasma
ratio, QrobF is the blood flow to the fetal body, V is the
tissue volumes, C is the concentration, Q is the blood flow,
KprobF is the fetal tissue partition coefficient, CLfa is the
estimated clearance from fetal blood to amniotic fluid, CLaf
is the estimated clearance from amniotic fluid to fetal
blood, and robF is the rest of the fetal body. The subscripts
amf, bloodF, and robF denote amniotic fluid, fetal blood,
and rest of fetal body, respectively.
The parameters used to model the feto-placental unit are
listed in Table 1. Simulated fetal plasma darunavir con-
centrations were comparable to observed cord blood con-
centrations (Fig. 4). From the observed clinical data, the
median (range) ratio for darunavir cord plasma/maternal
plasma was 0.2 (0.0–0.8) [22]. The simulated population
fetal plasma-to-maternal plasma concentration ratio over a
dosing interval is 0.30 (0.16–0.37).
3.5 Sensitivity Analysis
The results of the sensitivity analysis are shown in Fig. 5.
Changes in fetal darunavir tissue partitioning affected the
amplitude of the steady-state concentration-time profiles,
which corresponds to changes in Vss. The steady-state fetal
plasma concentration–time profiles were not affected by
the extent of darunavir clearance from the amniotic fluid to
fetal blood, mainly because clearance into and from
amniotic fluid was substantially lower than placental
clearance and partitioning into fetal tissue. This indicates
that, as previously observed [14], within physiologically
plausible ranges poorly informed assumptions made on
partitioning into amniotic fluid do not influence the out-
come of interest, i.e., fetal plasma concentrations. With
regard to changes in fraction unbound in fetal plasma and
MTF cotyledon clearance (parameterized proportionally),
both substantially impact the fetal plasma concentrations.
Therefore, precise (experimental) estimation and external
validity of these parameters is essential.
3.6 Exploratory Simulations of Fetal Exposure
to Darunavir at Different Doses
Based on the assumed exposure–effect relationship for
fetal antiviral activity, we conducted simulations to deter-
mine the optimal maternal dosing regimen with respect to
fetal treatment outcomes. We simulated a dose range for
both QD and BID maternal dosing (Fig. 6). These simu-
lations indicate that the standard dosing regimens result in
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therapeutic exposure to darunavir. However, if HIV-posi-
tive women have developed (multiple) resistance to pro-
tease inhibitors, possibly even higher dosing regimens are
optimal with regard to fetal benefit, especially in the case
of high-risk situations, such as maternal HIV breakthrough
at term.
4 Discussion
We developed a p-PBPK model for fetal drug exposure
during pregnancy that allowed us to predict the fetal
pharmacokinetics of ritonavir-boosted darunavir, at term.
In this study we introduced a feto-placental unit in the
model using bidirectional placental clearance parameters
determined separately from an ex-vivo human cotyledon
perfusion set-up.
To date, few p-PBPK models have simulated human
fetal PK profiles by integrating ex-vivo human placental
transfer parameters within a p-PBPK model. Two studies
report placental transfer of two other antiretroviral treat-
ments based on placental diffusion and placental elimina-
tion, using closed system, ex-vivo placental perfusion
experiments and non-linear compartmental modeling
[14, 15]. Although the derived physiological parameters
can be used to simulate fetal pharmacokinetics, it is chal-
lenging to precisely identify all the required parameters
using a one-way, closed-system perfusion setup [37].
The approach used in this study provides an alternative
to integrating placental transfer into p-PBPK models.
Bidirectional transfer parameters were determined sepa-
rately, by performing MTF and FTM perfusion experi-
ments. The placental clearances estimated from the current
ex-vivo experiments can be considered as whole organ
clearances and allowed inclusion of placental transfer as a
single barrier, rather than a compartmental structure with
corresponding flows, partitioning coefficients, and tissue
volumes. In terms of future development of more mecha-
nistic compartmental placental distribution models, for
instance for in-vitro-to-in-vivo extrapolation of placental
transfer data from passive permeability and placental active
transport studies, this approach in PBPK modeling may
provide a valuable starting point for verification steps.
With regard to the verification of simulated fetal expo-
sure to drugs in general, hardly any information is avail-
able. Preclinical studies indicate substantial fetal darunavir
exposure in rats, but extrapolation of these data to human
pregnancy is challenging [38]. Umbilical cord-to-plasma
concentration ratios in pregnant women taking darunavir/
ritonavir were reported [22]. Such data allow a rough
Fig. 5 Sensitivity analysis of feto-placental parameters. Sensitivity
analysis of feto-placental parameters with respect to fetal plasma
darunavir concentration–time profiles at steady state for darunavir/
ritonavir dosing regimens of 600/100 mg twice daily. The parameters
of interest include a fetal tissue partition coefficient), b amniotic
fluid-to-fetal blood clearance, c fraction unbound in fetal plasma, and
d maternal-to-fetal cotyledon clearance. conc. concentration
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verification of the model by comparing simulated profiles
with actual observed cord blood concentrations, as this is
the closest proxy for fetal exposure clinically and ethically
available [7]. The simulated fetal concentration–time pro-
file corresponds with the range of observed cord blood
concentrations, indicating that the developed darunavir
PBPK model provides a good approximation of the fetal
PK profile. The observed fetal plasma concentrations fol-
lowing darunavir 600 mg BID (Fig. 4c) show high vari-
ability. This can be misinterpreted as accumulation of the
drug, which is unlikely under steady-state conditions.
Caution is needed when interpreting concentration–time
profiles based on one observation per subject, with a lim-
ited amount of subjects, which is also the reason why data-
driven population pharmacokinetics is not an option in this
case. Consequently, we looked at the range rather than the
shape of these observed concentrations.
The observed FTM placental clearance in this study was
higher than MTF placental clearance. One explanation
could be that darunavir is a substrate for P-gp/ABCB1, an
efflux transporter located at the apical surface of placental
syncytiotrophoblast membrane. Darunavir efflux from tro-
phoblasts into the maternal plasma could therefore result in
relatively low MTF clearance. However, the experiment
was conducted in the presence of ritonavir, which is known
to inhibit P-gp, while also, P-gp functional expression is
expected to be low in the term placentas used in this study
because of reported gestational changes [39] Overall, the
role of transporters in regulating passage across the pla-
centa remains unclear [40, 41]. Because the system was
operated under sink conditions, the higher FTM clearance
can also be related by the higher flow rate in the maternal
compartment, which maintains a steeper concentration
gradient. Nevertheless, it is of note that the placental
clearance parameters determined from this experimental
set-up are based on physiological flows.
Because term placentas were used, the findings of this
study are limited mainly to drug administration at term.
Additionally, inferences on the impact of ritonavir con-
centrations on the darunavir placental transfer cannot be
made. In general, human ex-vivo cotyledon perfusion
experiments are limited to small numbers of term placen-
tas. Studies over a large concentration range or with pla-
centas from earlier stages of pregnancy are time consuming
and generally less feasible [6]. More data on placental
CYP450 expression, changes in hemodynamics, tissue
composition, and active uptake and efflux transport may
provide a better mechanistic basis for the description and
prediction of the placental transfer processes. Placental
transfer models could be developed that allow for the
simulation of fetal PK profiles in early pregnancy and fetal
exposure-response relationships, including drug–drug
interactions.
Another interesting finding in this study was the obser-
vation that cotyledon clearance did not correlate in a linear
manner with cotyledon weight. This is consistent with data
from a previous study, possibly indicating that tissue vol-
ume is a poor indicator of membrane surface area [42].
Based on this observation, the cotyledon clearance was
scaled per cotyledon assuming that with multiple perfusion
experiments, the population clearance per cotyledon is
approximated. Moreover, cutting the perfused part from the
remainder of the placenta is not very precise; therefore,
cotyledon weight was inappropriate to use for further
calculations.
With regard to the prevention of mother-to-child trans-
mission, vertical transmission of HIV from mothers with a
low or undetectable viral load can occur [43]. Successful
quantitative simulations of fetal exposure to antiretroviral
treatments provide a good basis for administering
antiretroviral agents for pre-exposure prophylaxis of the
fetus, but the actual clinical relevance is still under debate
[43]. Nevertheless, as shown by this study, p-PBPK models
can be employed as tools to optimize maternal pharma-
cotherapy to prevent fetal toxicity or enhance the devel-
opment of more selectively targeted, fetal drug treatments.
Fig. 6 Simulated fetal darunavir concentration-time profiles for
several darunavir dosing regimens. Simulated fetal darunavir con-
centration–time profiles for several maternal darunavir doses for
a once-daily (QD) dosing and b twice-daily (BID) dosing. The gray
dashed lines represent the therapeutic target trough concentration.
conc. concentration, DRV/r darunavir/ritonavir
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5 Conclusion
A p-PBPK model was developed to quantitatively predict
fetal exposure at term to the protease inhibitor darunavir
co-administered with ritonavir. By extending the existing
maternal PBPK model with a feto-placental unit, in-vitro-
to-in-vivo extrapolation was performed. If applied appro-
priately, the placental perfusion set-up is a valuable
experimental tool that can be integrated with PBPK mod-
eling to simulate fetal drug exposure during pregnancy.
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